Shandong Golden Brick Biotechnology Co., Ltd. Report issue

Academic/Hospital

Organization Overview

First Clinical Trial
2019
NCT04385641
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Shandong Golden Brick Biotechnology Co., Ltd.

Active Ingredients

Drugs in Other Trials (1)

umbilical cord mesenchymal stem cells (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1